Despite Near 30% Drop in Humira Sales, AbbVie Beats Wall Street’s Q2 Revenue Expectations

While Humira sales were impacted by cheaper biosimilars, AbbVie reported in its second-quarter earnings results Thursday that revenues jumped nearly 45% for Skyrizi and almost 56% for Rinvoq year over year, respectively.